Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis

Fig. 4

Serum protein profiling in the BLM-induced SSc model treated with MT-7117. Serum samples from mice treated with MT-7117 at 10 mg/kg and imatinib at 150 mg/kg from the BLM-induced SSc model (therapeutic model) were used for serum protein profiling. Using Luminex® assays, 110 proteins were investigated. The graphs showed 11 proteins that were significantly suppressed by MT-7117 treatment. All values are expressed as an individual plot dot and the mean ± SEM (n = 8). *p < 0.05, **p < 0.01 by Student’s t-test (vs. BLM_vehicle group)

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us